Mengke Pharmaceutical: Shareholder GeniePharma holding 10.92% of the shares publicly solicits voting rights to oppose certain resolutions.

Mingke Pharmaceuticals announced that shareholder GeniePharma voted against multiple proposals at the company's second extraordinary general meeting in 2025. GeniePharma holds a total of 71,572,817 shares in the company, accounting for 10.92% of the total shareholding. The period for collecting voting rights is from September 25, 2025 to October 6, 2025. The reasons for the opposition from the collector include uncertainties in the participation of Haijing Pharmaceuticals in the private placement fund, risks of channel and personnel confusion, slower progress in investment projects than expected, uncertainties in using Haijing Pharmaceuticals' production capacity to increase profitability, and limited synergies in the research and development field.